FGFR3 and non-small cell lung carcinoma: However, the ability to correctly establish the AREG/EREG-FGFR3 expression/activation status before and after Ctx-based therapies might better identify wt KRAS tumours with a high likelihood of Ctx response not only in the treatment of mCRC but also as a monotherapy or in combination with radiotherapy for recurrent or metastatic NSCLC after failing platinum-based chemotherapy and in SCC such as locally or regionally advanced HNSCC.